APIRx is managed by a best-in-class team of scientists, medical and manufacturing industry veterans with extensive experience and authority in the Cannabis Industry. APIRx’s independent Board of Directors is comprised of leading authorities in relevant industry sectors, providing objective perspective, strategic direction and network connections.

According to the research published by Ackrell Capital–“2018 Cannabis Investment Report”- the U.S. cannabis market generated $8 billion in 2017 and is expected to reach $10+ billion in 2018 from FDA-approved Cannabis-derivative pharmaceuticals. Ackrell estimates that the total market size will quadruple in the next five years to be $40 billion by 2023 and hit $125 billion by 2030, with the number of consumers exceeding 60 million.

APIRx is the world’s only company providing cGMP produced cannabinoid pharmaceutical and cannabinoid products. Prior to APIRx, the only cannabinoid acceptable to the FDA is dronabinol; a synthetic THC.

APIRx produces just as pure product but from a natural source with minimum or no alteration of the cannabinoids. There is no other provider in the marketplace that is capable of producing end-to-end cannabinoids based on 100% naturally grown cannabis plants.